New lipids therapy
April 6, 2016
EVOLOCUMAB, marketed as
Repatha in Australia, has been
hailed as a major advance in the
battle to manage a genetic type
of high cholesterol, called familial
hypercholesterolaemia, according
to a presentation at the American
College of Cardiology conference,
the Heart Foundation national ceo
Professor Garry Jennings has said.
“In Australia 80% of the 77,000
people predicted to have familial
hypercholesterolaemia are
undiagnosed,” he said, and this
new drug will work alongside
statins which still confer reduced
risk of heart attack for people with
high cholesterol.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Apr 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Apr 16